Prats-Uribe, A., Illingens, B., Vizcaya, D., Weaver, J., Burn, E., Sawant, R., . . . Evidence, E. H. D. (2020). Cardio- and cerebrovascular risk with conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS) in rheumatic arthritis (RA): A real-world comparative assesment.
Chicagoスタイル(17版)引用形式Prats-Uribe, A., et al. Cardio- and Cerebrovascular Risk with Conventional Synthetic Disease-modifying Antirheumatic Drugs (CSDMARDS) in Rheumatic Arthritis (RA): A Real-world Comparative Assesment. 2020.
MLA(9版)引用形式Prats-Uribe, A., et al. Cardio- and Cerebrovascular Risk with Conventional Synthetic Disease-modifying Antirheumatic Drugs (CSDMARDS) in Rheumatic Arthritis (RA): A Real-world Comparative Assesment. 2020.
警告: この引用は必ずしも正確ではありません.